First FDA/Alzheimer’s Disease Allies Meeting

ACT-AD, together with the Alzheimer’s Association and the Alzheimer’s Study Group, hosted and FDA/Alzheimer’s Disease Allies Meeting to stimulate an open discussion with FDA leadership on the subject of clinical meaningfulness in new AD therapies and help advance the dialogue regarding how best to measure the clinical effectiveness of emerging therapies.
View Agenda
See Press Release
Read Alzheimer Research Forum Article
View Transcript